Doxorubicin hydrochloride-associated renal failure

Area of Science:

• Nephrology
• Oncology
• Pharmacology

Background:

• Doxorubicin hydrochloride (Adriamycin) is a widely used chemotherapy agent.
• Anthracyclines, including doxorubicin, are known for potential cardiotoxicity and other adverse effects.
• Renal toxicity is a less commonly reported but significant adverse event associated with anthracycline therapy.

Observation:

• A case study of a 78-year-old male patient undergoing doxorubicin hydrochloride therapy revealed acute renal failure.
• The patient's pathophysiologic presentation mirrored findings observed with structural analogues of doxorubicin.
• Experimental data indicates that daunorubicin hydrochloride, an analogue, can induce renal failure in animal models.

Findings:

• Doxorubicin hydrochloride administration was directly associated with the onset of renal failure in the patient.
• The mechanism of renal injury appears consistent with that of other anthracyclines.
• Daunorubicin hydrochloride's known nephrotoxicity in animals supports the potential for doxorubicin-induced renal damage.

Implications:

• Close monitoring of renal function is crucial for patients receiving doxorubicin hydrochloride.
• This case highlights the importance of considering nephrotoxicity in the differential diagnosis of renal failure in cancer patients.
• Further research into the specific mechanisms of doxorubicin-induced nephrotoxicity may inform preventative strategies.